were enrolled. Only 4.5% were not assessable and 659 (86.5%) were able to answer the SATMED-Q. The oretical 6 factor solution explained 82.8% of the available variance; it was well defined, and all communalities were above 0.76. A strong correlation between Effectiveness and Impact on Daily Activities (r = 0.525) was found. Dimensional Cronbach's á ranged between 0.857 and 0.936. The one-dimensional ICC was 0.893 (0.890-0.905, 95% CI) and Guttman two-half index was 0.935. No significant correlation was found between age and Treatment Satisfaction (r = 0.055), Anxiety (r = −0.17), and Depression (r = 0.075). Neither between educational level and Anxiety (r = −0.038), but educational level showed to be related with Depression (r = −0.204; p < 0.001) and Treatment Satisfaction (r = 0.169; p < 0.001). Treatment Satisfaction dimension levels interact significantly with Depression (p < 0.001) and Anxiety (p < 0.011) severity levels. CONCLUSIONS: The psychometric properties of the SATMED-Q are good in this specific population. Significant differences in Treatment Satisfaction are found depending on the Anxiety and Depression level. OBJECTIVES: Multiple Sclerosis (MS) is a chronic neurological disease affecting the central nervous system with a prevalence rate of 240 per 100,000 in Canada. The prevalence of pain in MS ranges from 10%-80% (70% in a study we previously performed). Sativex® (SAT) is a new cannabis-based drug approved in Canada for neuropathic pain in patients with MS. Willingness-to-pay (WTP) elicits the extent of subjects' preference for their chosen treatment, expressed as the amount they would hypothetically be willing to pay in insurance premiums in order to have access to the treatment. METHODS: The WTP instrument had a decision board (DB) and a questionnaire. A DB is a visual aid to help clinicians present clinical information about treatment options in a standardized manner. Two treatment options were presented on the board used in this study, with text and data describing them obtained from clinical experts and the literature. The first option was a "cocktail" of three medications: gabapentin, amytriptylin, and acetaminophen ("pills"), while the comparator was the same "cocktail" but adding SAT ("pills and oral spray"). The WTP instrument was administered to 500 participants from the general Canadian population, using the bidding game approach. Descriptive statistics were calculated.
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PND14 TREATMENT OF NEUROPATHIC PAIN IN MULTIPLE SCLEROSIS: A POPULATION BASED WILLINGNESS-TO-PAY ANALYSIS

RESULTS:
The mean age of the study population was 39 ± 13 years, 56% were female. The DB was facilitated in English (85%) and French (15%). Of the 500 interviews conducted, 253 respondents chose the "pills and oral spray" option. For these subjects, the mean WTP per month in additional insurance premium was CAD $8 (range = $0-$200, median = $4). CON-CLUSION: Assuming only 51% in a general population are willing to pay additional premiums as reported, the obtained WTP would be able to fund the drug for all MS patients with pain (assumed 70%), with a remaining surplus of $3.24/person.
PND15
RELAPSING-REMITTING MULTIPLE SCLEROSIS (RR-MS) PATIENTS' VALUATION OF MS TREATMENT BENEFITS
Narewska J 1 , Lloyd A 1 , Dewilde S 2 , Hass SL 3 , Miller DW 3 1 United BioSource Corporation, London, UK, 2 United BioSource Corporation, Brussels, Belgium, 3 Elan Pharmaceuticals Inc, San Diego, CA, USA OBJECTIVES: This study used a stated preference discrete choice experiment (DCE) to explore the preferences and willingness to pay (WTP) of RR-MS patients in the UK regarding the benefits of treatments. METHODS: The attributes in the DCE included the number of future relapses, presence of new nerve damage, progression in disability level and out of pocket cost (to estimate WTP for changes in attribute levels). Participants were asked to indicate their preference for hypothetical treatment profiles that varied attribute levels based on an orthogonal fold-over design. The patient sample (n = 194) was recruited through advertisement with a patient advocacy group. WTP was estimated using logit analysis. RESULTS: Eighty-three percent of patients (mean age 44 years, 82% female) had experienced 1 or more relapses in the last 2 years and 46% required aid with ambulation. Patients had a mean annual household income of ≤33,000 and monthly MS-related expenditures of approximately ≤50. The estimated monthly WTP for a combined benefit of no disability progression, new nerve damage or relapses was approximately 9 times their current expenditures and 16% of their mean annual income. The most highly valued treatment outcome was avoidance of disability progression in the next year. Segmented analyses indicated that patients not currently experiencing a relapse and those with lower self-reported levels of disability had higher WTP for improvements in the other treatment benefit attributes. CONCLUSION: RR-MS patients indicated a differential demand for avoidance of MS related disability progression, relapses and nerve damage. Patients who were less severely affected by their RR-MS were willing to pay more to reduce the burden of their disease. This study underlines the high value patients place on the avoidance of MS sequelae, particularly disability progression.
OSTEOPOROSIS POS1 EFFECT OF COMORBIDITIES ON THE EARLY MORTALITY AFTER FEMORAL NECK FRACTURE IN ELDERLY IN HUNGARY
Sebestyén A 1 , Boncz I 1 , Tóth F 2 , Betlehem J 2 , Nyárády J 2 , Jeges S 2 1 National Health Insurance Fund Administration (OEP), Budapest, Hungary, 2 University of Pécs, Pécs, Hungary OBJECTIVES: Aim of our study is to analyse the 30 days mortality of patients over 60 with femoral neck fracture according to comorbidities at admission. METHODS: Data derives from the database of National Health Insurance Fund Administration and based on the S7200 code (femoral neck fracture) of International Classification of Diseases (ICD) tenth revision and the codes of comorbidities. The retrospective study is based on patients discharged in 2000 from the institutions providing definitive care after the primary treatment of femoral neck fracture. Financial data has been controlled with a nationwide institutional questionnaire. We calculated 30 days mortality as a time between hospital admission and death. Early mortality rates are presented according to the dominant occurrence most frequently found comorbidities. RESULTS: Altogether 3783 patients over 60 years met the inclusion criteria. The overall 30 days mortality was 9%. The mortality of patients with comorbidities was 9.65%, while without comorbidities it was 2.1%. The early mor-tality rate was the following in case of the most common comorbidities: Mental and behavioural disorders (F00-F99) 16.1%; Malignant neoplasms (C00-C97) 18.9%; Diabetes mellitus and other disorders of glucose regulation and pancreatic internal secretion (E10-E16) 10.4%; Extrapyramidal and movement disorders (G20-G26) 14.3%; Cerebrovascular diseases (I60-I69) 11.8%; Ischaemic heart diseases (I20-I25) 11.3%; Other forms of heart disease (I30-I52) 28.1%; Hypertensive diseases (I10-I15) 8%; decubitus ulcers (L89) 23%; Atherosclerosis (I70) 14.1%; Acute upper and lower respiratory infections (J00-J22) 43.9%; Chronic lower respiratory diseases (J40-J47) 14.3%. CON-CLUSIONS: The presence of comorbidities increases the chance for mortality. In order to decrease the risk of mortality, one has to treat the comorbidities also. The coexistence of several comorbidities, multiplies the chance of mortality. The mortality values after femoral neck fractures reveals the necessity of comorbidities' treatment emphasizing the importance of postoperative interdisciplinary cooperation.
POS2
LOSS OF TREATMENT BENEFIT DUE TO LOW COMPLIANCE WITH BISPHOSPHONATE THERAPY
Penning-van Beest FJA 1 ,Van den Boogaard CHA 1 , Erkens JA 1 , Olson M 2 , Herings RMC 1 1 PHARMO Institute, Utrecht, The Netherlands, 2 Novartis Pharma AG, Basel, Switzerland OBJECTIVES: To study the association between low compliance with bisphosphonate therapy and the risk of osteoporotic fracture. METHODS: New female users of daily or weekly alendronate or risedronate between 1999 and 2004, aged ≥45 years or with diagnosed post-menopausal osteoporosis were identified from the PHARMO database, including among others linked drug-dispensing and hospitalization data for over two million residents of The Netherlands. Patients were followed from their first bisphosphonate dispensing until their first hospitalisation for osteoporotic fracture, death, or end of the study period. Compliance with bisphosphonates during follow-up was measured over 90-day intervals using the Medication Possession Ratio (MPR), defined as the sum of days' supply of all alendronate and risedronate dispensed to each patient per 90-day interval. Data were analysed univariately and multivariately using time-dependent Cox regression analysis. RESULTS: The study cohort included 8822 new female users of alendronate or risedronate. During follow-up, 216 osteoporotic fractures occurred, of which 40 excluded fractures during the first 6 months. The percentage of non-compliant patients (MPR < 80%) increased from 34% after 6 months to 60% after 3 years of follow-up. Non-compliant bisphosphonate use was associated with a 40% increased risk of fracture (95% CI 4%-90%, adjusted for age and fracture history) compared to compliant bisphosphonate use. This corresponds to a 30% loss of treatment benefit. Classifying compliance into 5 categories, fracture risk gradually increased with poorer compliance (p trend < 0.05) to an 80% risk increase with very low compliance (MPR < 20%), corresponding to a 45% loss of treatment benefit. CONCLU-SIONS: The results of this study show a direct link between level of compliance with oral bisphosphonates and level of fracture risk. Thus, treatment compliance is vital to obtain maximal bone protection. To increase compliance, and therefore treatment benefit, the advent of bisphosphonates with more convenient dosing regimes is important.
POS3
KAPLAN-MEIER SURVIVAL ANALYSIS OF PATIENTS WITH MEDIAL AND LATERAL FEMORAL NECK FRACTURE OVER 60
Sebestyén A 1 , Boncz I 1 , Betlehem J 2 , Nyárády J 2 , Tóth F 2 1 National Health Insurance Fund Administration (OEP), Budapest, Hungary, 2 University of Pécs, Pécs, Hungary OBJECTIVES: The purpose of this study was to analyse the 5 year survival rate after medial femoral neck fracture according to type of fracture (medial or lateral) over 60. METHODS: The data derives from the financial database of the Hungarian National Health Insurance Fund Administration, based on the tenth revision of the International Classification of Diseases (ICD) with ICD code S7200 and on the Hungarian Diagnosis Related Group (DRG) system. The following patients were included into the study: having social insurance identification number, being discharged in 2000 after primary treatment of femoral neck fracture. The patients with polytrauma were excluded from the study. Statistical analysis was carried out with SPSS 14.0 for Windows. We created Kaplan-Meier survival curves (at 2170 days) and calculated chi-square values (Mantel-Cox log rank test). RESULTS: Altogether N = 3783 patients from the whole country were included into the study (mean age = 77.97 ± 8.513). 436 patients (mean age = 78.56 ± 8.934) had lateral while 3347 patients (mean age = 77.89 ± 8.456) had medial femoral neck fracture. One-way analysis of variance (ANOVA) showed no significant difference in the mean age of the two groups of patients (F = 2.594, P = 0.126). Overall survival at 5 years follow up was 29.36% for patients with lateral and 35.96% for patients with medial femoral neck fracture. Statistical analysis showed that type of fracture had a highly significant effect on mortality (log rank test 14.30, df = 1, p = 0.0002). CONCLUSIONS: We found significant difference in survival of patients depending on the type of femoral neck fracture (medial or lateral). Although survival is influenced by many other factors (e.g. co-morbidities, complications, etc.), the type of fracture is important. We emphasize the role of large administrative databases in order to analyse "real word" data.
POS4 COMPARING THE COST-EFFECTIVENESS OF RHBMP-2 IN THE TREATMENT OF OPEN TIBIA FRACTURES IN GERMANY, FRANCE, AND UK
Chhabra A 1 , Bentley A 2 , Oliver E 3 , Salaun B 4 , Greenberg D 5 , Alt V 6 1 Medtronic Europe Sarl, Tolochenaz, Switzerland, 2 Abacus International, Bicester, UK, 3 Medtronic Ltd, Watford, UK, 4 Medtronic France S.A.S, Boulogne, France, 5 Ben-Gurion University of the Negev, Beer-Sheva, Israel, 6 University Hospital Giessen-Marburg , Brackenheim, Germany OBJECTIVES: Recombinant human bone morphogenetic protein (rhBMP2) is a novel biologic therapy that promotes bone growth at the fracture site. We compared the cost and cost-effectiveness of rhBMP-2 in open tibia fractures in Germany, France and UK. METHODS: We developed an economic model to compare rhBMP-2 + standard of care (soft tissue management and intramedullary nailing) with standard of care alone. Clinical data was obtained from the BMP-2 Evaluation for Surgery in Tibial Trauma (BESTT) trial and cost data from the national tariffs (German-DRG, UK-NHS, French-Social Security tariffs), reported in 2005 values. Utility weights were assigned to different grades (Gustillo I-IIIB) of open tibia fractures and differences in treatment outcomes were calculated. We performed the analysis from payer's/health care system's perspective for a one year time-horizon. RESULTS: In Germany, use of rhBMP-2 for grade III open tibia fractures resulted in cost-savings of €4073 per patient that offsets the upfront cost of rhBMP2 (€2950), repre-
